Previous Article | Next Article ![]()
Journal of Virology, November 2001, p. 11010-11016, Vol. 75, No. 22
Microbiologie Médicale et
Moléculaire, Facultés de Médecine et Pharmacie,
Université de Bourgogne, 21033 Dijon
Cedex,1 and Unité de Virologie et
Immunologie Moléculaires, Institut National de la Recherche
Agronomique, 78352 Jouy-en-Josas,2 France
Received 30 January 2001/Accepted 10 August 2001
We investigated the rotavirus-specific lymphocyte responses induced
by intranasal immunization of adult BALB/c mice with rotavirus 2/6
virus-like particles (2/6-VLPs) of the bovine RF strain, by assessing
the profile of cytokines produced after in vitro restimulation and
serum and fecal antibody responses. The cytokines produced by splenic
cells were first evaluated. Intranasal immunization with 50 µg of
2/6-VLPs induced a high serum antibody response, including
immunoglobulin G1 (IgG1) and IgG2a, a weak fecal antibody response, and
a mixed Th1/Th2-like profile of cytokines characterized by gamma
interferon and interleukin 10 (IL-10) production and very low levels of
IL-2, IL-4, and IL-5. Intranasal immunization with 10 µg of 2/6-VLPs
coadministered with the mucosal adjuvants cholera toxin and
Escherichia coli heat-labile toxin (LT) considerably enhanced the Th1/Th2-like response; notably, significant levels of
IL-2, IL-4, and IL-5 were observed. Since rotavirus is an enteric pathogen, we next investigated the production of IL-2 and IL-5, as
being representative of Th1 and Th2 responses, by Peyer's patch and
mesenteric lymph node cells from mice immunized intranasally with
2/6-VLPs and LT. The results were compared to those obtained from
splenic and cervical lymph node cells. We found that both cytokines
were produced by cells from each of these lymphoid tissues. These
results confirm the Th1/Th2-like response observed at the systemic
level and show, on the assumption that T cells are the primary
cells producing the cytokines after in vitro restimulation, that
rotavirus-specific T lymphocytes are present in the intestine after
intranasal immunization with 2/6-VLPs and LT.
Rotaviruses are the most common
etiologic agents of severe acute gastroenteritis in infants and young
children throughout the world (8). The development of safe
effective rotavirus vaccines is an international priority, and
significant efforts have focused on live rotavirus vaccines
(10). New strategies including nonreplicating rotavirus
subunits, such as virus-like particles (VLPs), which are stable
noninfectious particles that are morphologically and antigenically
similar to the native virus, are also being investigated (1-4,
7, 11, 16, 17, 28). Rotavirus 2/6 VLPs (2/6-VLPs) are made by
coinfecting insect cells with recombinant baculoviruses expressing VP2
and VP6, the major core and intermediate layer proteins, which self
assemble spontaneously. Such VLPs have been shown to induce antibody
responses and protection from rotavirus challenge, notably in rabbits
after parenteral immunization (1) and in mice treated
orally and intranasally (16, 17). Until now, the profile
of cytokines induced by VLPs has not been investigated. In a previous
study, we showed that spleen cells from suckling mice orally inoculated
with highly replicative homologous or weakly replicative heterologous
strains of rotavirus produced a mixed Th1/Th2 pattern of cytokines,
including gamma interferon (IFN- Cells and viruses.
The MA-104 cell line, derived from
African green monkey kidney, was maintained in Eagle's modified
minimal essential medium supplemented with 2 mM
L-glutamine, nonessential amino acids, 100 U of penicillin
per ml, 100 µg of streptomycin per ml, and 5% heat-inactivated fetal
calf serum (FCS).
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.22.11010-11016.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Rotavirus 2/6 Virus-Like Particles Administered Intranasally in
Mice, with or without the Mucosal Adjuvants Cholera Toxin and
Escherichia coli Heat-Labile Toxin, Induce a
Th1/Th2-Like Immune Response

![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
), interleukin 5 (IL-5), and IL-10,
after in vitro restimulation (5). In the present study, we
first investigated the rotavirus-specific lymphocyte responses induced by intranasal immunization of adult BALB/c mice with 2/6-VLPs of the
bovine RF strain, by assessing antibody responses as well as the
profile of cytokines produced by splenocytes after in vitro restimulation with purified virus. We also investigated the effects of
cholera toxin (CT) and Escherichia coli heat-labile-toxin
(LT) adjuvants on these responses. Indeed, both adjuvants have been shown to significantly increase antibody responses and protection from
rotavirus challenge in mice immunized with VLPs (16, 17). We report that 2/6-VLPs administered intranasally induced a mixed Th1/Th2 profile of cytokines very similar to that induced by live rotavirus administered orally to suckling mice and that both CT and LT
considerably enhanced the mixed Th1/Th2-like immune response induced by
2/6-VLPs. Since rotavirus is an enteric pathogen and since there is a
substantial degree of compartmentalization within the mucosal immune
system (26), we next investigated the production of IL-2
and IL-5, as being representative of Th1 and Th2 responses, by Peyer's
patch (PP) and mesenteric lymph node (MLN) cells from mice immunized
with 2/6-VLPs in the presence of LT. This immunization schedule was
selected because of the high cytokine production observed in the first
experiments and of enhanced protection when VLPs are administered with
LT (16). The results were compared to those obtained from
splenic and cervical lymph node (CLN) cells. Both cytokines were found
to be produced by rotavirus-specific lymphocytes from each of these
lymphoid tissues after in vitro restimulation.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
VLP preparation and characterization. 2/6-VLPs were prepared in Sf9 cells coinfected at a high multiplicity of infection with BacRF2A and BacRF6 and purified as previously described (9). Briefly, infected cells were collected 5 days postinfection and then extracted with Freon 113, and the aqueous phase that contained VLPs was subjected to an isopycnic CsCl gradient in a 20 mM PIPES (piperazine-N,N'-bis[2-ethanesulfonic acid]) buffer with 10 µM CaCl2 (pH 6.6) (18 h at 35,000 rpm in a Beckman SW55 Ti rotor). Purified 2/6-VLPs were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis to confirm their protein composition and examined by negative-staining electron microscopy. Protein concentration was determined using a Bradford protein assay with BSA as the standard.
Immunization and sample collection.
Adult female BALB/c mice
(4 to 5 weeks old) were from our animal facilities for the first set of
experiments and from Iffa-Credo (L'Arbresle, France) for the second
one. No mice had evidence of previous rotavirus infection, as
determined by serum antibody titers. Mice were immunized intranasally
with 2/6-VLPs on days 0 and 14. Prior to intranasal inoculation, mice
were anesthetized by intraperitoneal administration of a mixture of
ketamine (80 mg/kg) and xylazine (16 mg/kg). The immunogen was given by
gradual inoculation of the nostrils of the mice. The different groups of mice received 50 µg of VLPs alone or 10 µg of VLPs mixed with 5 µg of CT or LT (both from Sigma, St Louis, Mo.) per dose in a volume
of 20 µl. Control mice received phosphate-buffered saline (PBS) with
or without CT or LT. To determine if a part of the immune response
observed could be attributed to the fact that a portion of the inoculum
may be swallowed, a group of five mice was immunized by the oral route
with 10 µg of 2/6-VLPs in the presence of 5 µg of LT. Blood and
fecal samples were collected from each mouse on day 35 (21 days after
the second immunization) and stored at
40°C prior to use. Mice were
then sacrificed, and spleens as well as, in one set of experiments,
superficial and posterior CLNs, PPs, and MLNs were removed.
Measurement of rotavirus-specific antibodies in serum and fecal
samples by ELISA.
Antibody titers in serum and fecal samples were
determined by ELISA. Microtiter plates were coated overnight at room
temperature with 100 µl of sucrose-purified RF virus (0.5 µg/ml in
0.1 M carbonate buffer, pH 9.6). Wells were blocked with PBS containing
5% nonfat dry milk. Fecal samples were made 10% (wt/vol) by
suspension in PBS, pH 7.4. Serial twofold dilutions in PBS-5% nonfat
dry milk of serum (starting at 1/100) or fecal extracts (starting at
1/40) were added to wells and incubated for 40 min at 37°C. After
three washes, the plates were incubated for 30 min at room temperature with a 1:5,000 dilution of biotin-labeled goat anti-mouse
,
,
1, or
2a heavy chain-specific antisera (Southern Biotechnology Associates, Inc., Birmingham, Ala.). The plates were washed, and peroxidase-labeled avidin (Southern Biotechnology Associates) was
added. The color reaction was developed at room temperature in the dark
with the chromogenic substrate orthophenylenediamine with 0.03%
H2O2, and
A492 was determined. Endpoint titers
were expressed as the reciprocal log10 of the
last dilution that gave an optical density at least twofold greater
than the mean value obtained with samples from uninfected mice for the
same dilution (cutoff value of 0.1). Negative serum samples (titer < 100) and fecal samples (titer < 40) were arbitrarily assigned
titers of 50 and 20 (twofold below 100 and 40), respectively, for
statistical calculations.
Preparation of spleen cells and superficial and posterior CLN,
PP, and MLN cells and in vitro restimulation.
Spleen and
superficial and posterior CLNs, PPs, and MLNs from each mouse were
aseptically removed, and single-cell suspensions were prepared by
mechanical dissociation. Cells were washed with incomplete medium
consisting of RPMI 1640 supplemented with 2 mM L-glutamine,
1 mM sodium pyruvate, 0.3% glucose, 100 U of penicillin per ml, and
100 µg of streptomycin per ml. After splenic erythrocytes had
been removed by lysis with sterile water, cells (4 × 106/ml) were resuspended in complete medium
(incomplete medium plus 10% heat-inactivated FCS). Cells from either
immunized or nonimmunized mice (4 × 105
cells/well) were cultured in the presence of 5 µg of sucrose-purified virus (RF or SA11 strain) per ml or RPMI medium only in 96-well plates.
In the second set of experiments, cells from spleens and superficial
CLNs were also cultured in the presence of 5 µg of VLPs per ml. The
T-cell mitogen concanavalin A (5 µg/ml) was added to positive control
wells. The cells were incubated at 37°C with 5%
CO2. The culture supernatants were harvested at
various intervals (days 2, 4, and 5) after restimulation, on the basis
of preliminary experiments, and frozen at
70°C until cytokine analysis.
Cytokine ELISA.
Cytokine levels in culture supernatants were
determined by ELISA. IFN-
, IL-2, and IL-4 levels were determined
using monoclonal antibodies (MAbs) obtained from PharMingen (San Diego,
Calif.). MAbs used for coating were clones R4-6A2 (2 µg/ml),
JES6-1A12 (2 µg/ml), and 11B11 (2 µg/ml), and MAbs used for
detection were clones XMG1.2 (0.5 µg/ml), JES6-5H4 (0.5 µg/ml), and
BVD6-24G2 (1 µg/ml) for IFN-
, IL-2, and IL-4, respectively.
Microtiter plates were coated with 50 µl of anticytokine MAb and
incubated overnight at 4°C. The wells were blocked with PBS
containing 3% BSA at room temperature for 2 h. After four washes
with PBS containing 0.05% Tween 20, 100 µl of supernatants was added
to duplicate wells and incubated overnight at 4°C. The plates were
then washed and incubated with the appropriate biotinylated
anticytokine MAb diluted in PBS with 3% BSA for 1 h. The plates
were washed, and peroxidase-labeled avidin was added and incubated for
30 min. The color reaction was developed with ABTS
(2,2'-azino-bis[3-ethylbenzthiazoline-6-sulfonic acid]) and 0.03%
H2O2. Standard curves were
generated using recombinant murine IFN-
(PeproTech, Rocky Hill,
N.J.), IL-4 (PharMingen), and IL-2 (PeproTech). The sensitivities of
these ELISAs were 15 pg/ml for IL-4, 5 pg/ml for IL-2, and 0.2 ng/ml
for IFN-
. Low levels of IL-4 were assessed using an ultrasensitive
kit (R&D Systems, Minneapolis, Minn.), and IL-5 and IL-10 levels were
measured using licensed kits (Endogen, Cambridge, Mass.) following the manufacturer's recommendations. The sensitivities of these ELISAs were
2 pg/ml for IL-4, 5 pg/ml for IL-5, and 12 pg/ml for IL-10. For
statistical analysis, levels of cytokine below the detection limit were
recorded as one-half the detection limit.
Statistics. Antibody responses and cytokine productions were both analyzed for comparison between the different groups with one-way analysis of variance, after verification of variance's homogeneity by using Hartley's table. For each antibody or cytokine analyzed, in the case of a significant one-way analysis of variance test, post hoc analysis comparing results between the different experimental arms was conducted by using a Newman-Keuls test. In the few cases where the measurements were performed for two groups only, a direct comparison was done using the Mann-Whitney nonparametric U test. Comparison of cytokine production under different conditions of restimulation within a given group were performed either by using a Newman-Keuls test after one-way analysis of variance or, when only two conditions were compared, by using the Mann-Whitney nonparametric U test. Similarly, within a given group, comparisons between serologic or fecal IgA and IgG responses were done by using the Mann-Whitney nonparametric U test. For all the tests, a P value of <0.05 was considered significant.
| |
RESULTS |
|---|
|
|
|---|
Fecal and serum antibody responses in mice inoculated
intranasally with 2/6-VLPs of the bovine RF strain of rotavirus with
and without CT or LT.
We examined the serum and fecal antibody
responses in mice inoculated twice intranasally either with 50 µg of
2/6-VLPs alone or with 10 µg of 2/6-VLPs in the presence of 5 µg of
CT or LT as well as in control mice that received PBS with or without
CT or LT. No significant antibody response was observed in control mice. All mice immunized with VLPs alone developed significant IgA and
IgG serologic responses (Fig. 1A). We
further characterized the systemic IgG response by assessing IgG1 and
IgG2a subclass responses. Elevated IgG1 and IgG2a levels were observed
(Fig. 1A). In fecal extracts, we could not detect any IgA response, whereas low levels of IgG were observed in all mice (Fig. 1B). The
coadministration of 10 µg of 2/6-VLPs with 5 µg of CT or LT induced
significantly higher titers of serum and fecal IgA and IgG antibody
than administration of 50 µg of 2/6-VLPs alone (P < 0.0002) (Fig. 1). Notably, a significant fecal IgA response was
observed (Fig. 1B). No statistically significant differences in fecal
and serum antibody responses were observed between mice that received
CT and LT as adjuvants (P > 0.05). 2/6-VLPs
administered with CT or LT induced higher titers of serum IgG than
serum IgA, whereas similar levels of IgG and IgA were observed in fecal
extracts. We further characterized the effects of CT and LT on the IgG
subclass response. Intranasal inoculation of 2/6-VLPs with CT or LT
induced significantly higher titers of both IgG1 and IgG2a than
intranasal administration of 2/6-VLPs alone (P < 0.0002) (Fig. 1A). No statistically significant differences in IgG1
response or in IgG2a response were observed between mice that received
CT and LT as adjuvants (P > 0.05).
|
Cytokine production by spleen cells from mice intranasally
inoculated with 2/6-VLPs of the bovine RF strain of rotavirus with and
without CT or LT.
We next examined the rotavirus-specific systemic
cytokine response induced by intranasal inoculation of 2/6-VLPs alone
or with CT or LT 3 weeks after the second immunization. IL-2, IFN-
, IL-4, IL-5, and IL-10 were assayed in culture supernatants from spleen
cells at different times after in vitro restimulation with purified
virus (RF or SA11 strain), on the basis of preliminary experiments (day
2 for IL-2, day 4 for IL-4 and IL-10, and day 5 for IFN-
and IL-5).
Residual production from in vivo priming was evaluated in wells
incubated without antigen in the presence of RPMI medium only. Spleen
cells from control mice that received PBS only or PBS with CT or LT did
not produce any cytokines after in vitro restimulation, and the results
for these groups were combined (Fig. 2).
|
and IL-10
production and very low levels of IL-2, IL-4, and IL-5, which were
higher than those observed for controls, although not significantly
different (Fig. 2). When 10 µg of 2/6-VLPs was administered
intranasally with CT or LT, a mixed Th1/Th2-like cytokine profile was
also induced and was characterized by IFN-
and IL-10 production as
well as significant levels of IL-2, IL-4, and IL-5 (Fig. 2). However,
some differences were observed between the two adjuvants. Mice
immunized with 10 µg of 2/6-VLPs and CT produced higher levels of
IL-2, IL-4, and IL-5 than mice immunized with 50 µg of 2/6-VLPs alone
(P = 0.0026, 0.043, and <0.0001, respectively),
whereas IL-10 levels were higher but not statistically different and
IFN-
levels were lower (P = 0.205 and 0.0218, respectively). Mice immunized with 10 µg of 2/6-VLPs and LT produced
higher levels of IL-2, IL-4, IL-5, and IL-10 than mice immunized with
50 µg of 2/6-VLPs alone but equivalent levels of IFN-
(P = <0.0001, 0.0002, 0.0016, 0.0015, and 0.172, respectively). Compared to mice immunized with 10 µg of 2/6-VLPs and
CT, mice immunized with 10 µg of 2/6-VLPs and LT produced higher
levels of IFN-
, IL-2, IL-4, and IL-10 but lower levels of IL-5
(P = 0.0021, <0.0001, 0.0069, 0.0126, and 0.0075, respectively).
For some mice in the three groups, a low residual production of some
cytokines resulting from in vivo priming was observed in wells
incubated without antigen in the presence of RPMI medium only.
Finally, levels of Th1 cytokines produced by spleen cells
restimulated with purified virus of the simian SA11 strain (serotype
G3) were not statistically different from those produced when purified
virus of the bovine RF strain (serotype G6) was used for restimulation
(P > 0.05) (Fig. 2). Although levels of Th2 cytokines
produced by spleen cells restimulated with RF were higher than those
obtained after SA11 restimulation, we observed a statistically
significant difference only for IL-4 levels in mice immunized with
2/6-VLPs and CT (P = 0.04).
IL-2 and IL-5 production by spleen cells and superficial and
posterior CLN, PP, and MLN cells from mice immunized intranasally or
orally with 2/6-VLPs and LT.
Since rotavirus is an enteric
pathogen and since mucosal immune responses may be stronger at sites
adjacent to the site of induction than at more distant sites, we
investigated IL-2 and IL-5 production, as being representative of Th1
and Th2 cells, respectively, by PP and MLN cells from mice intranasally
immunized twice with 10 µg of 2/6-VLPs and LT. This immunization
schedule was selected because it induced a strong production of both
cytokines in the first set of experiments and of enhanced protection
when VLPs are administered with LT (16). We also
investigated IL-2 and IL-5 production from splenic and CLN (superficial
and posterior lymph nodes) cells, where antigen-sensitized lymphocytes
migrate after intranasal immunization (21, 25). Controls
were inoculated with PBS and LT. Finally, to determine if a portion of
the intranasal inoculum which might have been swallowed contributed to
the immune response at the intestinal level, we also investigated IL-2
and IL-5 production by the different lymphoid tissues after oral
immunization with 10 µg of 2/6-VLPs and 5 µg of LT. Cells from
spleens, CLNs (superficial and posterior), PPs, and MLNs from control
mice that received PBS with LT did not produce significant levels of
IL-2 or IL-5 (Fig. 3).
|
| |
DISCUSSION |
|---|
|
|
|---|
Recent studies have shown that the intranasal route of
immunization with rotavirus VLPs or inactivated rotavirus particles induced higher levels of antibody responses and protection in mice than
oral immunization (15-17). Moreover, CT and LT have been shown to significantly increase antibody responses and protection against rotavirus infection in adult CD-1 mice intranasally immunized with VLPs (16, 17). In the present study, we investigated the rotavirus-specific lymphocyte responses induced by intranasal administration of 2/6-VLPs of the bovine RF strain of rotavirus to
adult BALB/c mice with and without the mucosal adjuvants CT and LT.
2/6-VLPs intranasally administered alone induced a rotavirus-specific systemic Th1/Th2-like cytokine response very similar to that produced by spleen cells from suckling mice orally inoculated with highly replicative homologous or weakly replicative heterologous strains of
rotavirus (5). Indeed, spleen cells from mice immunized with 2/6-VLPs produced, after in vitro restimulation with purified rotavirus, IFN-
, IL-10, and very low levels of IL-2, IL-4, and IL-5.
This mixed Th1/Th2-like cytokine profile was in accordance with the
fact that both IgG1 and IgG2a were produced. These results indicate
that rotavirus antigens induce similar systemic cytokine responses
under very different experimental conditions.
We also examined the lymphocyte responses after coadministration by the
intranasal route of 2/6-VLPs with CT or LT. As previously reported for
CD-1 mice, we found that rotavirus-specific antibody titers were
greatly enhanced; notably, high fecal IgA and IgG titers were induced
by administration of 10 µg of 2/6-VLPs with adjuvants, compared to
the very weak fecal antibody response induced by 50 µg of 2/6-VLPs
alone. Whether these fecal antibody responses are mucosa associated or
serum derived remains to be determined. Concerning the cytokine
response, we found that CT and LT significantly increased both Th1- and
Th2-like cytokine production by spleen cells compared to immunization
with 2/6-VLPs alone. In support of this, a strong upregulation of both
serum IgG1 and IgG2a isotypes was observed. However, enhancement was
not observed for all the cytokines assessed, and some differences were
observed between CT and LT. Whereas IL-2, IL-4, and IL-5 production was
greatly enhanced when a fivefold-lower dose of 2/6-VLPs was used with both adjuvants, IFN-
production was either lower or equivalent, according to the adjuvant, and IL-10 was not upregulated with CT. This
observation suggests that upregulation of cytokine production by CT and
LT may be dissociated, the major effect concerning cytokines which are
not produced when 2/6-VLPs were administered alone. Although it seemed
that the immune response with CT was more Th2-like than that with LT,
due to higher levels of IL-5 (Th2 type), its effects should be
considered not purely Th2 but rather mixed. Indeed, we observed a
strong increase in both IgG1 and IgG2a levels as well as an increase in
Th1 (IL-2) and Th2 (IL-4 and IL-5) cytokine levels. Several studies
have reported that oral or intranasal immunization of mice with tetanus
toxoid and CT induced a strict Th2 response (12, 13, 27).
However, a mixed Th1/Th2 immune response with CT has also been shown,
in particular after intranasal immunization of mice with a human
immunodeficiency virus type 1 peptide and CT (19) and
after oral or intranasal immunization of macaques with p55 of simian
immunodeficiency virus and CT (6, 14). These conflicting
results remain to be explained; in particular, differences in antigens
should be considered. With LT as adjuvant, both IgG1 and IgG2a titers
were enhanced as well as Th1 and Th2 cytokine levels. Our results
support other studies which showed that oral immunization with tetanus
toxoid and LT or intranasal immunization with Helicobacter
urease and LT induced a mixed Th1 and Th2 response (20,
24). Moreover, McNeal et al. (15) found that
inclusion of LT-R192G, an attenuated E. coli heat-labile enterotoxin, during intranasal immunization with inactivated rotavirus particles caused increases in both serum IgG1 and IgG2a titers without
significant change in IgG1/IgG2a ratios.
Since rotavirus is an enteric pathogen and because it has become evident that mucosal immune responses are stronger at sites adjacent to the site of induction than at more distant sites, we next investigated cytokine production at the intestinal level. IL-2 and IL-5 production, representative of Th1 and Th2 cells, respectively, was assessed in PPs and MLNs from mice immunized twice intranasally with 10 µg of 2/6-VLPs and LT. This immunization schedule was selected because of the high immune response induced in the first set of experiments and of enhanced protection when VLPs are administered with LT (16). Both cytokines were also investigated in spleens and CLNs (superficial and posterior), where antigen-sensitized lymphocytes migrate after intranasal immunization (21, 25). We found that, after intranasal immunization, rotavirus-specific cells producing high levels of IL-2 and IL-5 could be detected not only in spleens and CLNs but also in PPs and MLNs. Since after in vitro restimulation, cytokines are most likely produced by T cells, these results suggest that rotavirus-specific T lymphocytes are present in the intestine after intranasal immunization. This is in accordance with recent results reporting the presence of memory T cells in intestinal lymphoid tissue after intranasal inoculation of mice with the SAG1 protein of Toxoplasma gondii with CT (23) and Cryptosporidium parvum DNA (18) and of memory B cells in pigs inoculated with rotavirus 2/6-VLPs in the presence of LT (28). In our study, residual production of cytokines by VLP-induced effector cells still present 3 weeks after the second immunization was observed in some cases in wells incubated without antigen and should be deducted from the total response to assess the memory responses.
Although mice were anesthetized during immunization, we could not rule out the possibility that a portion of the intranasal inoculum was swallowed and contributed to the immune response induced by 2/6-VLPs at the intestinal level. To discard this hypothesis, IL-2 and IL-5 were also investigated after oral inoculation of mice under the same conditions. IL-2 and IL-5 production was significantly lower than in mice inoculated by the intranasal route, with detectable production being observed in only two of the five mice orally given 2/6-VLPs and LT. This result eliminates the possibility that a part of the immune response observed at the intestinal level was due to antigen swallowed during intranasal inoculation. Moreover, it is in accordance with previous results showing increased immunogenicity and protection after intranasal administration of VLPs compared to oral immunization (16, 17). Of interest, IL-2 and IL-5 production was detected in superficial CLNs from the two mice for which a response was observed after oral immunization, as was previously reported after immunization with bacterial protein antigens in the presence of CT (25).
In conclusion, we have shown that 2/6-VLPs of the bovine RF strain of rotavirus administered intranasally to adult BALB/c mice generated a rotavirus-specific cytokine response characterized by a mixed Th1/Th2 profile similar to that induced by oral inoculation of live rotavirus in suckling mice. Coadministration of VLPs with CT or LT considerably enhanced this mixed Th1/Th2 response, and this effect correlated with a large increase in fecal and serum antibody responses. Finally, rotavirus-specific production of both IL-2 and IL-5 was observed in PPs and MLNs after intranasal immunization with 2/6-VLPs in the presence of LT, suggesting the presence of rotavirus-specific T lymphocytes in these lymphoid tissues. Further testing will be required to determine if these results might be influenced by the strain of mouse.
| |
ACKNOWLEDGMENTS |
|---|
The first two authors contributed equally to this work.
C. Fromantin died before this work was completed. We appreciate her generous contributions, both scientific and personal, over the years. We thank Annie Charpilienne for the preparation and characterization of the VLPs.
This work was supported by grants from the Conseil Régional de Bourgogne and from the Ministry of Research attributed to the Réseau de Recherche sur les Gastro-entérites à Rotavirus: Epidémiologie, Structure et Interaction avec l'hôte.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratoire de Microbiologie Médicale et Moléculaire, Facultés de Médecine et Pharmacie, Université de Bourgogne, 7 boulevard Jeanne d'Arc, 21033 Dijon Cedex, France. Phone: 33 3 80 29 34 37. Fax: 33 3 80 29 36 04. E-mail: Evelyne.Kohli{at}u-bourgogne.fr.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ciarlet, M.,
S. E. Crawford,
C. Barone,
A. Bertolotti-Ciarlet,
R. F. Ramig,
M. K. Estes, and M. E. Conner.
1998.
Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity.
J. Virol.
72:9233-9246 |
| 2. |
Coste, A.,
J. C. Sirard,
K. Johansen,
J. Cohen, and J. P. Kraehenbuhl.
2000.
Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea.
J. Virol.
74:8966-8971 |
| 3. |
Crawford, S. E.,
M. K. Estes,
M. Ciarlet,
C. Barone,
C. M. O'Neal,
J. Cohen, and M. E. Conner.
1999.
Heterotypic protection and induction of a broad heterotypic neutralization response by rotavirus-like particles.
J. Virol.
68:5945-5952 |
| 4. | Fernandez, F. M., M. E. Conner, D. C. Hodgins, A. V. Parwani, P. R. Nielsen, S. E. Crawford, M. K. Estes, and L. J. Saif. 1998. Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from cows immunized with recombinant SA11 rotavirus core-like particle (CLP) or virus-like particle (VLP) vaccines. Vaccine 16:507-516[CrossRef][Medline]. |
| 5. | Fromantin, C., L. Piroth, I. Petitpas, P. Pothier, and E. Kohli. 1998. Oral delivery of homologous and heterologous strains of rotavirus to BALB/c mice induces the same profile of cytokine production by spleen cells. Virology 244:252-260[CrossRef][Medline]. |
| 6. |
Imaoka, K.,
C. J. Miller,
M. Kubota,
M. B. McChesney,
B. Lohman,
M. Yamamoto,
K. Fujihashi,
K. Someya,
M. Honda,
J. R. McGhee, and H. Kiyono.
1998.
Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues.
J. Immunol.
161:5952-5958 |
| 7. | Jiang, B., M. K. Estes, C. Barone, V. Barniak, C. M. O'Neal, A. Ottaiano, H. P. Madore, and M. E. Conner. 1999. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 17:1005-1013[CrossRef][Medline]. |
| 8. | Kapikian, A., and R. Chanock. 1996. Rotaviruses, p. 1657-1708. In B. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven Publishers, Philadelphia, Pa. |
| 9. |
Labbe, M.,
A. Charpilienne,
S. E. Crawford,
M. K. Estes, and J. Cohen.
1991.
Expression of rotavirus VP2 produces empty corelike particles.
J. Virol.
65:2946-2952 |
| 10. | Lynch, M., J. S. Bresee, J. R. Gentsch, and R. I. Glass. 2000. Rotavirus vaccines. Curr. Opin. Infect. Dis. 13:495-502[CrossRef][Medline]. |
| 11. | Madore, H. P., M. K. Estes, C. D. Zarley, B. Hu, S. Parsons, D. Digravio, S. Greiner, R. Smith, B. Jiang, B. Corsaro, V. Barniak, S. Crawford, and M. E. Conner. 1999. Biochemical and immunologic comparison of virus-like particles for a rotavirus subunit vaccine. Vaccine 17:2461-2471[CrossRef][Medline]. |
| 12. |
Marinaro, M.,
P. N. Boyaka,
R. J. Jackson,
F. D. Finkelman,
H. Kiyono,
E. Jirillo, and J. R. McGhee.
1999.
Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
J. Immunol.
162:114-121 |
| 13. | Marinaro, M., H. F. Staats, T. Hiroi, R. J. Jackson, M. Coste, P. N. Boyaka, N. Okahashi, M. Yamamoto, H. Kiyono, H. Bluethmann, K. Fujihashi, and J. R. McGhee. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621-4629[Abstract]. |
| 14. | McGhee, J. R., H. Kiyono, M. Kubota, S. Kawabata, C. J. Miller, T. Lehner, K. Imaoka, and K. Fujihashi. 1999. Mucosal Th1- versus Th2-type responses for antibody- or cell-mediated immunity to simian immunodeficiency virus in rhesus macaques. J. Infect. Dis. 179(Suppl. 3):S480-S484. |
| 15. |
McNeal, M. M.,
M. N. Rae,
J. A. Bean, and R. L. Ward.
1999.
Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles.
J. Virol.
73:7565-7573 |
| 16. |
O'Neal, C. M.,
J. D. Clements,
M. K. Estes, and M. E. Conner.
1998.
Rotavirus 2/6 virus-like particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge.
J. Virol.
72:3390-3393 |
| 17. | O'Neal, C. M., S. E. Crawford, M. K. Estes, and M. E. Conner. 1997. Rotavirus virus-like particles administered mucosally induce protective immunity. J. Virol. 71:8707-8717[Abstract]. |
| 18. | Sagodira, S., S. Iochmann, M. N. Mevelec, I. Dimier-Poisson, and D. Bout. 1999. Nasal immunization of mice with Cryptosporidium parvum DNA induces systemic and intestinal immune responses. Parasite Immunol. 21:507-516[CrossRef][Medline]. |
| 19. | Staats, H. F., W. G. Nichols, and T. J. Palker. 1996. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J. Immunol. 157:462-472[Abstract]. |
| 20. | Takahashi, I., M. Marinaro, H. Kiyono, R. J. Jackson, I. Nakagawa, K. Fujihashi, S. Hamada, J. D. Clements, K. L. Bost, and J. R. McGhee. 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173:627-635[Medline]. |
| 21. | Tilney, N. L. 1971. Patterns of lymphatic drainage in the adult laboratory rat. J. Anat. 109:369-383[Medline]. |
| 22. |
Tosser, G.,
M. Labbe,
M. Bremont, and J. Cohen.
1992.
Expression of the major capsid protein VP6 of group C rotavirus and synthesis of chimeric single-shelled particles by using recombinant baculoviruses.
J. Virol.
66:5825-5831 |
| 23. |
Velge-Roussel, F.,
P. Marcelo,
A. C. Lepage,
D. Buzoni-Gatel, and D. T. Bout.
2000.
Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into both NALT and GALT compartments.
Infect. Immun.
68:969-972 |
| 24. | Weltzin, R., H. Kleanthous, F. Guirakhoo, T. P. Monath, and C. K. Lee. 1997. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine 15:370-376[CrossRef][Medline]. |
| 25. | Wu, H. Y., E. B. Nikolova, K. W. Beagley, J. H. Eldridge, and M. W. Russell. 1997. Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization. Infect. Immun. 65:227-235[Abstract]. |
| 26. | Wu, H. Y., and M. W. Russell. 1997. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol. Res. 16:187-201[Medline]. |
| 27. |
Xu-Amano, J.,
H. Kiyono,
R. J. Jackson,
H. F. Staats,
K. Fujihashi,
P. D. Burrows,
C. O. Elson,
S. Pillai, and J. R. McGhee.
1993.
Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues.
J. Exp. Med.
178:1309-1320 |
| 28. |
Yuan, L.,
A. Geyer,
D. C. Hodgins,
Z. Fan,
Y. Qian,
K. O. Chang,
S. E. Crawford,
V. Parreno,
L. A. Ward,
M. K. Estes,
M. E. Conner, and L. J. Saif.
2000.
Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs.
J. Virol.
74:8843-8853 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»